ArticleCell death discovery2026
Unlocking ferroptosis heterogeneity: ATF4 versus SREBF transcriptional programs.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Regulated cell death (RCD) encompasses diverse forms induced by common cellular stressors, including oxidative stress and endoplasmic reticulum stress. Cells may display features from multiple RCD types, implying coexistence of "pure" and "mixed" forms of cell death. Ferroptosis is an iron-dependent form of RCD characterized by lipid peroxide accumulation and absence of specific biomarkers. Its regulation is heterogeneous and pathway-dependent, reflecting the broader complexity of the RCD spectrum. This study hypothesized two major regulatory pathways governing ferroptosis induction and functioning. The first pathway operates through GPX4, a central enzyme preventing ferroptosis by reducing lipid peroxides. Genetic GPX4 knockout and chemical GPX4 inhibition with ML210 resulted in significant upregulation of mevalonate pathway regulators SREBF1 and SREBF2, indicating compensatory anti-ferroptotic activation through the mevalonate pathway. The second pathway functions through the Xc⁻/GSH system critical for glutathione synthesis. System Xc⁻ inhibition leads to intracellular cysteine depletion with subsequent glutathione depletion, inducing ferroptotic cell death. SREBF transcription factor cascades were downregulated in system Xc⁻/GSH depletion experiments, contrasting with GPX4 inhibition responses. Instead, the system Xc⁻/GSH pathway is primarily governed by ATF4 to maintain cystine uptake and glutathione biosynthesis under stress conditions. These findings confirm ferroptosis as a heterogeneous spectrum of cell death with multiple interacting yet mechanistically distinct pathways. Moreover, these data provide a dynamic multi-omics resource for further ferroptosis research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.